BioSpace News Archive

Amarin Corporation plc today announced that it will host a conference call with members of Amarin senior management to discuss the company’s first quarter 2020 financial results and provide an operational update on Thursday, April 30, 2020, at 7:30 a.m. ET.

TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 first quarter financial results on Tuesday, May 12, 2020.

No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA)

VOYAGER did not meet the primary endpoint of an improvement in progression-free survival for avapritinib versus regorafenib in patients with third- or fourth-line GIST

The Board of Directors of BD has declared a quarterly dividend of $0.79 per common share, payable on June 30, 2020 to holders of record on June 9, 2020.

Forma Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced the appointment of David N. Cook, Ph.D., to the leadership team as senior vice president and chief scientific officer.

Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET..

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020.

Data from Phase 3 clinical trial demonstrate statistically significant effect achieved at all pre-specified primary endpoints

ZENITH20 Phase 2 clinical trial amended to include new dosing regimens aimed at improving therapeutic index Management to host webcast and conference call today to review data and program strategy at 8:30 a.m. ET